PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.21%
R&D growth 1.1-1.25x TRAW's 11.42%. Bill Ackman would demand evidence of superior returns.
-38.56%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
-22.93%
Other expenses reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency.
-7.06%
Operating expenses reduction while TRAW shows 7.45% growth. Joel Greenblatt would examine advantage.
-7.06%
Total costs reduction while TRAW shows 7.45% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-22.93%
Both companies reducing D&A. Martin Whitman would check industry patterns.
7.02%
EBITDA growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
7.06%
Operating income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
148.79%
Other expenses growth while TRAW reduces costs. John Neff would investigate differences.
10.36%
Pre-tax income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.36%
Net income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
28.30%
EPS growth while TRAW declines. John Neff would investigate advantages.
28.30%
Diluted EPS growth while TRAW declines. John Neff would investigate advantages.
24.68%
Share count reduction below 50% of TRAW's 9.47%. Michael Burry would check for concerns.
24.68%
Diluted share reduction below 50% of TRAW's 9.47%. Michael Burry would check for concerns.